Molecular screening for relapsed small cell lung cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This protocol focuses on molecular screening for patients with relapsed small cell lung cancer, utilizing DNA extracted from archived or fresh tissue and blood samples. The study employs next-generation sequencing (NGS) and Nanostring CNV testing, along with immunohistochemistry and FISH analysis, to profile the molecular characteristics of tumors. The molecular profiling can occur before, during, or after initial treatment, and aims to identify patients who may qualify for subsequent drug intervention studies based on their molecular profiles.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Provision of fully informed consent prior to any study specific procedures.
2. Patients must be ≥20 years of age.
3. Histologically or cytologically confirmed Small cell lung cancers
4. ECOG performance status of 0 to 2
5. Patients who are being treated or were treated with platinum-based chemotherapy as a first-line treatment
6. Patients with available archival tissues for molecular analysis or patients who agreed with biopsy for molecular analysis

Exclusion Criteria:

1. More than two prior chemotherapy regimen for the treatment of small cell lung cancer
2. Pregnant or nursing women (women of reproductive potential have to agree to use an effective contraceptive method)
3. Patients with second primary cancer, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for ≤2 years.

Where it's running

• Samsung Medical Center
  Seoul, South Korea Recruiting
• Gachon University Gil Medical Center
  Incheon, South Korea Completed
• Chungbuk University Hospital
  Jungbuk, South Korea Completed
• Seoul National University Bundang Hospital
  Seongnam, South Korea Completed
• VHS Medical Center
  Seoul, South Korea Completed
• Ulsan University Hospital
  Ulsan, South Korea Completed

Study contacts

• Principal investigator: Se-Hoon Lee, MD, PhD — Samsung Medical Center
• Study coordinator: Se-Hoon Lee, MD,Ph.D.
• Email: sehoon.lee@samsung.com
• Phone: +82-10-4759-7640

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Autologous B7-H3 CAR T Cells in Advanced Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer

  This study tests a patient’s own B7-H3 CAR T cells to see if they can help people 18 and older whose small cell lung cancer or EPNEC has come back or hasn’t responded to prior treatment.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07509034

• ZG006 plus ZG005 for advanced small cell lung cancer and neuroendocrine carcinoma

  This trial tests whether the combination of ZG006 and ZG005 helps adults with advanced small cell lung cancer or neuroendocrine carcinoma.

  Recruiting Phase 1/2 Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Guanzhou, Guangdong · NCT07038096

• Tarlatamab versus standard chemotherapy for pre-treated advanced pulmonary (large-cell) or gastroenteropancreatic poorly differentiated neuroendocrine carcinomas

  This trial tests whether tarlatamab helps adults with DLL3-positive, pre-treated advanced pulmonary (large-cell) or gastroenteropancreatic poorly differentiated neuroendocrine carcinomas compared with standard chemotherapy.

  Recruiting at 40 sites Phase 3 Intergroupe Francophone de Cancerologie Thoracique · Angers and 39 other locations · NCT06937905

• Testing a new treatment for advanced neuroendocrine tumors

  This study is testing a new treatment combining a virus with two cancer drugs to see if it helps people with advanced neuroendocrine tumors feel better and tolerate the treatment well.

  Recruiting Phase 1 University of Miami · Miami, Florida · NCT06889493

• Targeted alpha therapy [212Pb]VMT-Alpha-NET for SSTR-positive metastatic or inoperable GI neuroendocrine, pheochromocytoma/paraganglioma, small cell lung, kidney, and head & neck cancers

  This trial will try an experimental targeted alpha-particle drug called [212Pb]VMT-Alpha-NET in adults whose metastatic or inoperable tumors show somatostatin receptor (SSTR) expression.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06479811

• Testing ZG006 for advanced small cell lung cancer and neuroendocrine carcinoma

  This study is testing a new drug called ZG006 to see if it is safe and effective for people with advanced small cell lung cancer or neuroendocrine carcinoma.

  Recruiting Phase 1/2 Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Beijing, Beijing Municipality · NCT06440057

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.